Biodexa Pharmaceuticals
4.21
-0.09 (-2.09%)
At close: Jan 14, 2025, 3:58 PM
4.20
-0.24%
After-hours Jan 14, 2025, 06:27 PM EST
undefined%
Bid 3.8
Market Cap 978.13M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -73.22
PE Ratio (ttm) -0.06
Forward PE n/a
Analyst Buy
Ask 5.5
Volume 5,734
Avg. Volume (20D) 289,236
Open 4.32
Previous Close 4.30
Day's Range 4.13 - 4.32
52-Week Range 3.50 - 74.00
Beta undefined

About BDRX

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and ...

Industry Biotechnology
Sector Healthcare
IPO Date Dec 7, 2015
Employees 21
Stock Exchange NASDAQ
Ticker Symbol BDRX

Analyst Forecast

According to 1 analyst ratings, the average rating for BDRX stock is "Buy." The 12-month stock price forecast is $200, which is an increase of 4650.59% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
3 months ago · Source
-30.12%
Bioedexa Pharmaceuticals shares are trading lower.... Unlock content with Pro Subscription
3 months ago · Source
+67.66%
Biodexa Pharmaceuticals shares are trading higher after the company announced it successfully appealed Nasdaq's delisting decision and was granted a time extension to demonstrate compliance with its listing rule.